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ABSTRACT
Current wound management for chronic diabetic ulcers is unreliable and frequently
fails. Due to this unsatisfactory outcome, many diabetic patients are at risk for further
complications such as amputations or death. Hyperbaric oxygen therapy (HBOT) has the
potential to promote chronic diabetic ulcer healing as an adjunct treatment tool by reducing
tissue hypoxia and ischemia. The purpose of this medical literature review is to examine the
effect of HBOT, compared to standard wound care alone, on chronic diabetic lower extremity
ulcer healing. Unfortunately, limitations of existing medical evidence hinder the use of HBOT as
a conventional treatment modality for non-healing diabetic wounds. Further discussion involves
diabetic lower extremity ulcer etiology, normal wound healing physiology, chronic wound
physiology in diabetic patients, and present HBOT research.
INTRODUCTION
Chronic lower extremity ulcers are a common complication seen in diabetic patients.
Currently there is no defined treatment regimen used to heal chronic diabetic wounds
effectively and to ultimately decrease the associated costs and risks involved. In the United
States, it is estimated that 15% of diabetic patients develop foot ulcers, and 14-24% of those
patients will require an amputation.1 The average cost of healing a single non-infected ulcer is
$8,000, and the average cost for a major amputation is $45,000. In addition, about 50% of
people with amputations will develop ulcers in the opposite limb within 18 months, and the
three-year mortality after one amputation is estimated to be 20-50%.2 Due to these facts, there
is debate whether hyperbaric oxygen therapy (HBOT) can play an effective role as an adjunct
tool in the chronic wound repair process.3-8
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Wound management has evolved substantially over the years to promote healing in
different types of cutaneous injuries through various treatment regimens. However, there are
several situations that make the wound healing process a grueling challenge. These conditions
include extensive burns, ischemia, venous or arterial insufficiency, immune compromise, and
pressure areas.9 One of the most common diseases that yields complication in the wound
healing process, eventually leading to chronic wound status, is diabetes.3 Non-healing lower
extremity ulcers are a prevalent complication among the diabetic population, potentially
leading to a decline in quality of life, and even amputation and death.4 The chronic ulcers
frequently arise from complications of diabetic neuropathy, peripheral vascular disease, edema,
calluses, or trauma. The wounds require extensive treatment practices such as tissue
debridement, infection control, and pressure relief. However, many of the treatments leave
these patients with poor results.2-4
A chronic diabetic ulcer is described to be any lower extremity wound that has been
present for over one month and where attempts to heal by standard wound care methods have
failed. Standard wound care is considered to be any localized treatment, such as topical
ointments or solutions, dressings, or tissue debridement.8,9 One possible solution to treating
non-healing diabetic ulcers is the addition of HBOT to current treatment regimens. HBOT is the
administration of 100% oxygen exposure at a high pressure, generally around 2-3 atmosphere
absolute (ata) pressure, for several minutes once or twice daily. It is performed by placing the
patient’s body in a pressurized chamber and allowing them to breathe the concentrated oxygen
in order to increase the availability for body tissues. The role of HBOT as a modality for chronic
wound treatment is to maintain tissue oxygen saturation for several hours after therapy
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sessions; therefore, stimulating and continuing the healing process.6-8 Although chronic diabetic
ulcers involve hyperglycemia in addition to ischemia, HBOT may demonstrate benefit as
supplementary care by acting on the ischemic portion of the chronic wounds. The purpose of
this literature review is to examine the effect of HBOT, compared to standard wound care
alone, on wound healing in chronic diabetic lower extremity ulcers, up to one year after
treatment. It is important to identify new treatment regimens for chronic diabetic ulcers in
order to improve quality of life and prevent further complications such as amputation.
DISCUSSION
Normal wound healing consists of three confluent phases: inflammatory, proliferative,
and tissue remodeling (Fig. 1).10 The inflammatory phase consists of vessel constriction and
platelet aggregation. It begins immediately after the wound injury occurs and continues for four
to six days. Next, the proliferative phase involves granulation, blood vessel formation, and reepithelization. This process can take a few weeks to complete. Finally, the tissue remodeling
phase concludes the entire process via wound contraction and fibroblast activation, which
ultimately leads to wound closure. This phase can take up to a couple years. The first two
stages utilize acute hypoxia and reactive oxygen species (ROS) activity to begin and promote
the healing process, while oxygen recovery in the third phase enables completion of the
process. Throughout the healing series, vascular endothelin growth factor (VEGF) plays an
important role for the development and maintenance of blood vessels, endothelin-1 is
necessary for vasoconstriction to essentially maintain vascular tone, and interleukin 6 (IL-6) has
both pro-inflammatory and anti-inflammatory action that promote wound closure.8,10,11
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Excerpted from Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in
acute and chronic wound healing. Br J Dermatol. 2010;163(2):257-268. doi:10.1111/j.13652133.2010.09804.x
Fig 1. Normal physiologic phases of the wound healing process and corresponding activity
response over time. Chronic wound physiology is also represented by continuation of the
inflammatory phase.10
In chronic wounds, such as lower extremity diabetic ulcers, the normal events of wound
healing are not accomplished. Many factors not only contribute to the etiology, they play a role
in the prevention of wound closure as well. Some of these causes include tissue hypoxia,
bacterial overgrowth, and ischemia. Due to these issues, chronic wounds remain in the
inflammatory phase and cannot progress to full tissue healing (Fig. 1).10 This is also true for
chronic diabetic ulcers. With the persistence of tissue hypoxia, vascular insufficiency, immune
incompetence and hyperglycemia, many diabetic ulcers remain in the first phase of the healing
process and thus become chronic. The continuation of the ulcers can then lead to further
complications that greatly affect quality of life (e.g. disability or amputation), or even threaten
patient lives.
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HBOT is considered to be an adjunct treatment modality to promote diabetic ulcer
healing by ending the ongoing hypoxic and ischemic state of the chronic wounds. This idea is
demonstrated in a study conducted on rats, which investigates the role of HBOT in ischemic
and/or hyperglycemic wound states. It was found that the ischemic and hyperglycemic wounds
that underwent HBOT (experimental groups) had decreased wound size and less closure time
when compared to the control groups. However, there was no significant difference found in
wound contraction and re-epithelialization between the groups. In addition, ischemic wounds
in hyperglycemic conditions benefited the most from HBOT.12 Based on these results, HBOT
may possess the potential to promote ulcer healing in diabetic patients.
In data collected from 971 diabetic patients that underwent HBOT, it was found that
wounds with a modified Wagner grading of 3 or higher showed the most benefit from HBOT. It
was also found that the greatest wound healing appeared within the first fifteen treatments.
Amputation rates were seen to be doubled in patients with interrupted treatments as opposed
to those with uninterrupted therapy sessions.6 This suggests that patients with more extensive
ulcers may benefit most from HBOT, as opposed to less severe wounds. Nevertheless, the study
was retrospective and did not incorporate a control group.
Additionally, HBOT was found to significantly impact VEGF, enothelin-1 and IL-6 plasma
levels. In a study that examined chronic wounds and their responses to HBOT, it was found that
VEGF and IL-6 levels significantly increased after each treatment session, whereas endothelin-1
progressively decreased over the sessions. These level changes promoted angiogenesis,
regulation of vascular tone, and decreased inflammation in the wounds, ultimately leading to
faster and complete wound closures.8 By utilizing HBOT, chronic wounds have a greater
5

potential to break out of a prolonged inflammatory phase, and progress through the remaining
stages of the healing process. Unfortunately, the study included a small sample size and various
chronic wound etiologies, as opposed to focusing primarily on diabetic ulcers.
Although HBOT is considered safe at common treatment pressures, there are still risks
involved. Complications are categorized as either pressure- or oxygen-related. These include
middle ear barotrauma, sinus squeeze, pulmonary barotrauma, seizures, myopia,
claustrophobia, and pulmonary-related oxygen toxicity. The most frequent adverse event
experienced during treatment is middle ear barotrauma, which is also the most common
reason for termination of HOBT. Nevertheless, the majority of complications are benign and
treatable. To decrease the risk, it is recommended that patients be evaluated before, during,
and after each session. It is also important that operational protocols are set and followed for
each session. When these precautions are followed, HBOT is considered a safe treatment
modality.7,13
CONCLUSION
The effect of HBOT on chronic diabetic lower extremity ulcer healing appears to be
more beneficial than standard wound care alone. Based on current studies, adding HBOT to
treatment regimens may promote complete chronic wound healing, and at a quicker rate. This
response is due to the influence of HBOT on tissue oxygenation and stimulation of the proper
wound healing cycle. Ultimately, HBOT may end the persistence of chronic diabetic ulcers, and
thus decrease the necessity for amputations and the risk of developing other complications.
Although HBOT has the potential to positively impact chronic diabetic wounds, more
research must be conducted in order to make it a common treatment modality. Current
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research has demonstrated the beneficial effect of HBOT; however, many of the supporting
studies include small sample sizes, numerous chronic wound etiologies, experimentation on
animals, various treatment protocols, etc. In order to make a strong recommendation for the
use of HBOT in diabetic patients with chronic lower extremity ulcers, more research must be
performed on larger numbers of patients with diabetic wounds, and specific treatment
protocols need to be established. It is also important to determine the cost effectiveness of
HBOT and establish which types of chronic diabetic ulcers will benefit most from the therapy. In
conclusion, current therapies for chronic diabetic wounds regularly have poor outcomes;
therefore, it is essential to find new treatment regimens. HBOT may prove to be a promising
adjunct modality to standard wound care, and if this is the case, it can positively impact the
quality of life and mortality rates in diabetic patients.
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